evidence: The Commission on Human Medicine (CHM) has advised that given the end of the Autumn 2022 booster campaign and the stable safety profile of the COVID-19 vaccines, the MHRA should transition to routine data publication and communication of safety concerns for COVID-19 vaccines. This report is therefore the last regular publication of the Summary of Yellow Card reporting for COVID-19 vaccines. [...] All vaccines and medicines have some side effects although not everybody gets them. These side effects need to be continuously balanced against the expected benefits in preventing illness. As part of the MHRA’s responsibility to ensure that the benefits of the COVID-19 vaccines used in the UK continue to outweigh the risks, the MHRA is closely monitoring the bivalent mRNA vaccines and COVID-19 vaccine Novavax using the proactive pharmacovigilance surveillance strategy in place for the initial vaccine rollout. We also work closely with our public health partners in reviewing the effectiveness and impact of the vaccines to ensure the benefits continue to outweigh any possible side effects. Our ongoing review of suspected adverse events following the launch of the National Autumn 2022 booster campaign has not revealed any new safety concerns. [...] The Commission on Human Medicines (CHM) advises ministers on the safety, efficacy and quality of medicinal products. For COVID-19 vaccines, the CHM has a COVID-19 Vaccines Safety Surveillance Methodologies Expert Working Group and a COVID-19 Vaccines Benefit Risk Expert Working Group.